Two posters were presented at the ASH meeting from the NCI trial:
"Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy." Abstract #2042; Presenter: Dr.
This study analyzed the product characteristics and biological activity of the anti-CD19 CAR T cells and concluded that anti-CD19 CAR T cells are polyfunctional, capable of producing a broad range of immune modulating cytokines, chemokines and effector molecules that peak sequentially.
This analysis included 17 patients treated with a low dose conditioning chemotherapy regimen (cyclophosphamide 300-500 mg/m2/day and fludarabine 30 mg/m2/day for 3 days) of which 10 received anti-CD19 CAR T cells that were manufactured under a new process, which was co-developed with Kite. The objective response rate was 71% (35% complete remission (CR)) overall and 70% (40% CR) among those treated with cells manufactured using the new process. Grade 3 or 4 cytokine release syndrome or neurotoxicity was observed in 59% of patients and was generally reversible.
"Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy." Abstract #4426; Presenter: Dr.
The clinical researchers found that the conditioning regimen of cyclophosphamide and fludarabine triggered changes in several key cytokines and chemokines that could drive expansion, activation, and trafficking of CAR T cells. Preliminary results suggest that the magnitudes of rise in interleukin-15 and reduction in perforin are associated with objective responses.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the continued progress and success of the NCI's clinical trials under the CRADA between
Kite Pharma Cynthia M. ButittaChief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin JacksonFor Investor Inquiries: Lisa Burns Burns McClellan212-213-0006 firstname.lastname@example.org email@example.com
News Provided by Acquire Media